Cardiovascular System

  • Ali Hall
Part of the Pediatric Oncology book series (PEDIATRICO, volume 22)


Graft Versus Host Disease Primary Pulmonary Hypertension Hepatic Venous Pressure Gradient Bone Marrow Trans Anthracycline Therapy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Baglin T, Harper P, Marcus R, (1990) Veno-occlusive disease of the liver complicating ABMT successfully treated with recombinant tissue plasminogen activator (rtPA). Bone Marrow Transplantation 5(3):439–441PubMedGoogle Scholar
  2. Bearman SI, Appelbaum FR, Buckner CD, Petersen FB Fisher LD, Clift RA, Thomas ED (1988) Regimen-related toxicity in patients undergoing bone marrow transplantation. Journal of Clinical Oncology 6(10):1562–1568PubMedGoogle Scholar
  3. Bu Lock FA, Mott MG, Oajhill A, Martin RP (1996) Early identification of anthracycline cardiomyopathy: possibilities and implications. Archives of Disease in Childhood 75(5):416–422PubMedGoogle Scholar
  4. Cancer Therapy Evaluation Program (2003) Common Terminology Criteria for Adverse Events, Version 3.0.DCTD, NCI, NIH, DHHS March 31, 2003. June 10Google Scholar
  5. Grenier MA, Lipshultz SE (1998) Epidemiology of anthracycline cardiotoxicity in children and adults. Seminars in Oncology 25(4 Supp 10):72–85PubMedGoogle Scholar
  6. Hrstkova H, Brazdova Z, Novotny J, Bajer M (2001) Nutrition and exercise in the lifestyle of long-term survivors of childhood cancer. Scripta Medica Facultatis Medicae Universitatis Bruensis Masarykianae 74(6):379–390Google Scholar
  7. Iarussi D, Indol. P, Galderisi M, Bossone E (2000) Cardiac toxicity after anthracycline chemotherapy in childhood. Herz 25(7):676–688PubMedGoogle Scholar
  8. Jensen BV, Neilson SL, Skovsgaard T (1996) Treatment with angiotensin-converting-enzyme inhibitor for epirubicin-induced dilated cardiomyopathy. Lancet 347(8997):297–299PubMedGoogle Scholar
  9. Kremer LC, van der Pal HJ, Offringa M, van Dalen EC, Voute PA (2002) Frequency and risk factors of subclinical cardiotoxicity after anthracycline therapy in children: a systemic review. Annals of Oncology 13(6):819–829PubMedGoogle Scholar
  10. Langebrake C, Reinhardt D, Ritter J (2002) Minimising the long-term adverse effects of childhood leukaemia therapy. Drug Safety 25(15):1057–1077PubMedGoogle Scholar
  11. Lanzarini L, Bossi G, Laudisa ML, Klersy C, Arico M (2000) Lack of clinically significant cardiac dysfunction during intermediate dobutamine doses in long-term childhood cancer survivors exposed to anthracyclines. American Heart Journal 140(2):315–323PubMedGoogle Scholar
  12. Lanzkowsky, P (1999) Manual of Pediatric Hematology, 3rd edn. London, Academic PressGoogle Scholar
  13. Levitt G, Bunch K, Rogers CA, Whitehead B (1996) Cardiac transplantation in childhood cancer survivors in Great Britain. European Journal of Cancer 32A(5):826–830PubMedGoogle Scholar
  14. Lipshultz SE, Giantris AL, Lipshultz SR, Kimball Dalton V, Asselin BL, Barr RD, et al. (2002) Doxorubicin administration by continuous infusion is not cardioprotective: the Dana-Farber 91-01 acute lymphoblastic leukemia protocol. Journal of Clinical Oncology 20(6):1677–82PubMedGoogle Scholar
  15. Lopez M (1999) Dexrazoxane. Current status and prospectives of cardiotoxicity of chemotherapy. Clinica Terapeutica 150(1):37–49PubMedGoogle Scholar
  16. Oeffinger KC, Buchanan GR, Eshelman DA, Denke MA, Andrews C, Germak JA, Tomlinson GE, Snell LE, Foster BM (2001) Cardiovascular risk factors in young adult survivors of childhood acute lymphoblastic leukemia. Journal of Pediatric Hematology/Oncology 23(7):424–430PubMedGoogle Scholar
  17. Ortega JA, Donaldson SS, Ivy SP, Pappo A, Maurer HM (1997) Venoocclusive disease of the liver after chemotherapy with vincristine, actinomycin D and cyclophosphamide for the treatment of rhabdomyosarcoma. A report of the Intergroup Rhabdomyosarcoma Study Group, Children’s Cancer Group, the Pediatric Oncology Group, and the Pediatric Intergroup Statistical Centre Cancer 70(12):2435–2439Google Scholar
  18. Reiss U, Cowan M, McMillan A & Horn B, (2002) Hepatic venoocclusive disease in blood and bone marrow transplantation in children and young adults: incidence, risk factors and outcome in a cohort of 241 patients. Journal of Pediatric Hematology and Oncology 24(9):746–750Google Scholar
  19. Richardson PG, Elias AD, Krishnan A, Wheeler C, Nath R, Hoppensteadt D, Kinchla NM, Neuberg D, Waller EK, Antin JH, Soiffer R, Vredenburgh J. Lill M. Woolfrey AE, Bearman SI, Iacobelli M, Fareed J, Guinan EC (1998) Treatment of severe veno-occlusive disease with defibrotide: compassionate use results in response without significant toxicity in high-risk population. Blood 92(3):737–744PubMedGoogle Scholar
  20. Speyer J, Wasserheit C (1998) Strategies for reduction of anthracycline cardiac toxicity. Seminars in Oncology 25(5):525–537PubMedGoogle Scholar
  21. Trobaugh-Lotrarion A, Greffe B, Deterding R, Deutsch G, Quinones R (2003) Pulmonary veno-occlusive disease after autologous bone marrow transplant in a child with stage iv neuroblastoma: case report and literature review. Journal of Pediatric Hematology and Oncology 25(5):405–409Google Scholar
  22. Vogelsang G B, Dalal J (2002) Hepatic venoocclusive disease in blood and bone marrow transplantation in children: incidence, risk factors and outcome. Journal of Pediatric Hematology and Oncology 24(9):706–709Google Scholar
  23. Evans M, Gibson F (1999) Paediatric Oncology: Acute Nursing Care. London, WhurrGoogle Scholar
  24. Lilleyman J, Hann I, Blanchette V, (2000) Pediatric Hematology, 2nd edn. Edinburgh, Churchill LivingstonGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2005

Authors and Affiliations

  • Ali Hall

There are no affiliations available

Personalised recommendations